Family · Pharmaceutical analytical standards
Safinamide
A selective, reversible inhibitor of MAO-B, the enzyme that breaks down dopamine, which also reduces glutamate release: approved in Europe in 2015 as an add-on to levodopa in Parkinson's disease. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was discovered in Italy and first studied as an antiepileptic: only later did research focus on Parkinson's disease.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
